MetaVia (NASDAQ:MTVA) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

MetaVia (NASDAQ:MTVA) posted its earnings results on Thursday. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.03), Zacks reports.

MetaVia Stock Down 0.8%

NASDAQ MTVA traded down $0.01 during trading hours on Thursday, hitting $1.19. 64,112 shares of the company were exchanged, compared to its average volume of 148,932. The company has a 50 day moving average of $1.40 and a two-hundred day moving average of $4.58. MetaVia has a 52-week low of $0.97 and a 52-week high of $19.03. The firm has a market cap of $6.14 million, a price-to-earnings ratio of -0.14 and a beta of 0.59.

Analysts Set New Price Targets

Several research firms have recently commented on MTVA. Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a research report on Friday, April 24th. HC Wainwright lowered their target price on MetaVia from $40.00 to $20.00 and set a “buy” rating for the company in a report on Friday, March 27th. Finally, Wall Street Zen upgraded shares of MetaVia from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $26.50.

Hedge Funds Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new stake in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent SEC filing. 1.37% of the stock is currently owned by hedge funds and other institutional investors.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.